Target intelligence / Profile preview

Carnosine synthase (CARNS1)

Target
CARNS1
Molecular classification
Enzyme, Ligase (specifically peptide synthase)
01

Overview

The "Carnosine synthesis pathway" is not itself a single molecular target but refers to the **biosynthetic process** that produces the dipeptide carnosine from its constituent amino acids, β-alanine and L-histidine[3][4]. The key enzyme responsible for this reaction is **carnosine synthase** (CARNS1), which catalyzes the ATP-dependent condensation of β-alanine and L-histidine to form carnosine[1][2][4]. This enzyme belongs to the ligase class (EC 6.3.2.11) and is sometimes referred to as "carnosine synthetase"[5]. Carnosine itself plays important roles in muscle tissue as a pH buffer, antioxidant, metal chelator, regulator of calcium ions and enzymes, and inhibitor of protein glycosylation[5][6]. The pathway also includes related enzymes such as **carnosinase** (for degradation) and **carnosine N-methyltransferase** for methylated analogs like anserine[1][4]. Because "Carnosine synthesis pathway" describes a metabolic process rather than a discrete molecular entity or druggable target such as an enzyme or receptor, it should not be considered a canonical therapeutic target on its own—rather, its key component enzyme (**carnosine synthase/CARNS1**) is the relevant molecular target. Therefore: - The correct canonical name for targeting purposes would be "**Carnosine synthase**". - The abbreviation is "**CARNS1**". - It is an **enzyme**, specifically a ligase. - If you are seeking structured information about drug targets or biomarkers related to this pathway/process rather than individual molecules/enzymes within it ("pathway" vs "target"), then this entry should be marked as incorrect (`is_incorrect: true`) because pathways are not direct therapeutic targets; their constituent enzymes/proteins are. If you need information on specific drugs or inhibitors/modulators acting on CARNS1/carnosinases or other components in this pathway, there currently appear to be no approved drugs directly targeting these enzymes in clinical use[2][4].

Other names
Carnosine synthetaseATP-grasp domain-containing protein 1EC 6.3.2.11
02

Biological functions

Synthesis of carnosine from β-alanine and L-histidineRegulation of muscle pH bufferingAntioxidant activity (indirectly via carnosine production)
03

Disease associations

Neurodegenerative disease (potential role via carnosine’s neuroprotective effects)Muscle fatigue/aging-related decline

Beyond the preview

Go deeper on Carnosine synthase (CARNS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Carnosine synthase (CARNS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call